These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Jacobetz MA; Chan DS; Neesse A; Bapiro TE; Cook N; Frese KK; Feig C; Nakagawa T; Caldwell ME; Zecchini HI; Lolkema MP; Jiang P; Kultti A; Thompson CB; Maneval DC; Jodrell DI; Frost GI; Shepard HM; Skepper JN; Tuveson DA Gut; 2013 Jan; 62(1):112-20. PubMed ID: 22466618 [TBL] [Abstract][Full Text] [Related]
7. Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform. Ko AH; Kim KP; Siveke JT; Lopez CD; Lacy J; O'Reilly EM; Macarulla T; Manji GA; Lee J; Ajani J; Alsina Maqueda M; Rha SY; Lau J; Al-Sakaff N; Allen S; Lu D; Shemesh CS; Gan X; Cha E; Oh DY Oncologist; 2023 Jun; 28(6):553-e472. PubMed ID: 36940261 [TBL] [Abstract][Full Text] [Related]
8. Targeting the Tumor Stroma: the Biology and Clinical Development of Pegylated Recombinant Human Hyaluronidase (PEGPH20). Wong KM; Horton KJ; Coveler AL; Hingorani SR; Harris WP Curr Oncol Rep; 2017 Jul; 19(7):47. PubMed ID: 28589527 [TBL] [Abstract][Full Text] [Related]
9. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. O'Neil BH; Scott AJ; Ma WW; Cohen SJ; Aisner DL; Menter AR; Tejani MA; Cho JK; Granfortuna J; Coveler L; Olowokure OO; Baranda JC; Cusnir M; Phillip P; Boles J; Nazemzadeh R; Rarick M; Cohen DJ; Radford J; Fehrenbacher L; Bajaj R; Bathini V; Fanta P; Berlin J; McRee AJ; Maguire R; Wilhelm F; Maniar M; Jimeno A; Gomes CL; Messersmith WA Ann Oncol; 2015 Sep; 26(9):1923-1929. PubMed ID: 26091808 [TBL] [Abstract][Full Text] [Related]
10. Update on phase I studies in advanced pancreatic adenocarcinoma. Hunting in darkness? Strimpakos AS; Saif MW JOP; 2013 Jul; 14(4):354-8. PubMed ID: 23846926 [TBL] [Abstract][Full Text] [Related]
11. Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study. Petrioli R; Roviello G; Fiaschi AI; Laera L; Marrelli D; Roviello F; Francini E Cancer Chemother Pharmacol; 2015 Apr; 75(4):683-90. PubMed ID: 25618415 [TBL] [Abstract][Full Text] [Related]
12. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. Scheithauer W; Schüll B; Ulrich-Pur H; Schmid K; Raderer M; Haider K; Kwasny W; Depisch D; Schneeweiss B; Lang F; Kornek GV Ann Oncol; 2003 Jan; 14(1):97-104. PubMed ID: 12488300 [TBL] [Abstract][Full Text] [Related]
13. Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. Rogers JE; Mizrahi JD; Xiao L; Mohindroo C; Shroff RT; Wolff R; Varadhachary GR; Javle MM; Overman M; Fogelman DR; Raghav KPS; Pant S; McAllister F Cancer Med; 2020 Aug; 9(15):5406-5415. PubMed ID: 32519420 [TBL] [Abstract][Full Text] [Related]
14. Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer. Dalgleish AG; Stebbing J; Adamson DJ; Arif SS; Bidoli P; Chang D; Cheeseman S; Diaz-Beveridge R; Fernandez-Martos C; Glynne-Jones R; Granetto C; Massuti B; McAdam K; McDermott R; Martín AJ; Papamichael D; Pazo-Cid R; Vieitez JM; Zaniboni A; Carroll KJ; Wagle S; Gaya A; Mudan SS Br J Cancer; 2016 Sep; 115(7):789-96. PubMed ID: 27599039 [TBL] [Abstract][Full Text] [Related]
15. Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the 'burden of therapy' method. Haas M; Waldschmidt DT; Stahl M; Reinacher-Schick A; Freiberg-Richter J; Fischer von Weikersthal L; Kaiser F; Kanzler S; Frickhofen N; Seufferlein T; Dechow T; Mahlberg R; Malfertheiner P; Illerhaus G; Kubicka S; Abdul-Ahad A; Snijder R; Kruger S; Westphalen CB; Held S; von Bergwelt-Baildon M; Boeck S; Heinemann V Eur J Cancer; 2021 Mar; 146():95-106. PubMed ID: 33588150 [TBL] [Abstract][Full Text] [Related]
16. Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer. Rajeshkumar NV; Yabuuchi S; Pai SG; Tong Z; Hou S; Bateman S; Pierce DW; Heise C; Von Hoff DD; Maitra A; Hidalgo M Br J Cancer; 2016 Aug; 115(4):442-53. PubMed ID: 27441498 [TBL] [Abstract][Full Text] [Related]
17. Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma. Shui L; Cheng K; Li X; Shui P; Zhou X; Li J; Yi C; Cao D BMC Cancer; 2020 Jul; 20(1):636. PubMed ID: 32646394 [TBL] [Abstract][Full Text] [Related]
18. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Colucci G; Giuliani F; Gebbia V; Biglietto M; Rabitti P; Uomo G; Cigolari S; Testa A; Maiello E; Lopez M Cancer; 2002 Feb; 94(4):902-10. PubMed ID: 11920457 [TBL] [Abstract][Full Text] [Related]
19. HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer. Doherty GJ; Tempero M; Corrie PG Future Oncol; 2018 Jan; 14(1):13-22. PubMed ID: 29235360 [TBL] [Abstract][Full Text] [Related]